A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital approach to connecting patients with suitable clinic
It has been a busy week for psychedelic medicines developer Cybin, marked by a breakthrough designation (BTD) from the FDA for its depression therapy, new clinical data, a
Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it
Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.
Armed with new phase 3 data, Bayer has started to prepare for filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin